Radnostix INIS
OTC INIS
$0.04 +0.00 (+0.00%)
At close: Nov 9, 2026 · 4:00 PM EST

Radnostix (INIS) Non-Current Deferred Revenue (2018 - 2019)

Updated

Radnostix (INIS) reported Non-Current Deffered Revenue of $7,500 for Q3 2019, unchanged from the prior quarter.

Analysis

Radnostix (INIS) Non-Current Deferred Revenue (2018 - 2019) Analysis & Trends

Dating back to Q4 2018, Radnostix's Non-Current Deffered Revenue record includes 4 quarters.

  • Per Business Quant data, the three quarters before Q3 2019 came in at $7,500 (Q2 2019), $7,500 (Q1 2019) and $7,500 (Q4 2018).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,261.99 Bn 1,235.61 Bn 20.46 Bn
2 Johnson & Johnson 678.93 Bn 598.79 Bn 17.30 Bn
3 AbbVie 518.29 Bn 486.30 Bn 13.12 Bn
4 Merck 365.98 Bn 328.92 Bn 13.19 Bn
5 Novartis Ag 316.85 Bn 290.09 Bn -
6 Astrazeneca 293.40 Bn 267.29 Bn 13.26 Bn
7 Amgen 251.78 Bn 203.43 Bn 7.58 Bn
8 Gilead Sciences 210.61 Bn 185.71 Bn 6.73 Bn
9 Pfizer 166.87 Bn 114.23 Bn 12.56 Bn
10 Radnostix 20.37 Mn 14.48 Mn 1.36 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2019 7,500.00
Jun 30, 2019 7,500.00
Mar 31, 2019 7,500.00
Dec 31, 2018 7,500.00
API Access

Radnostix Non-Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=INIS&period=max&api_key=YOUR_API_KEY